Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 25.35+4.1%5:20 PM EDTNews

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fitzhughlaw who wrote (12159)10/22/2010 9:33:25 AM
From: idahoranch11 Recommendation  Read Replies (1) of 46680
The market pricing in biotech's is all over the map. HGSI was less than 50 cents a share last year, DNDN was under #2.75, I'm sure I could find several examples that would look much like that.

$4 doesn't price ANY of IMMU's pipeline products as being successful, NONE. For that matter, $12 doesn't either, all $12 would suggest is that the market has raised the possibility of success in a product.

I'm not invested in this company for market sentiment. There are those who would buy shares at $3 betting on the greater fool theory, that someone will pay them more than they paid because of past stock action. That is fine, that makes a market, but it doesn't take into consideration an approved hPAM4 or E-mab.

If an offer of $12 or $15 came in, it would be from a company that feels the market is mis-pricing the company, and more than likely it would be offering a low ball number as compared to what it thinks the company is worth.

Since UCB has access to information that we (the market) doesn't, I doubt they could mount a takeover since they would have insider information, just like they probably can't buy shares. They know data we don't know, long term SLE data, etc.

If anyone noticed, on slide #89 in Dr. Leonard's presentation, it said that the ALL trial with E-mab should reach the target enrollment this year. The key primary outcome measure is "Event free survival at 4 months", so it won't take long to finish evaluating the data in this trial, could be by the end of the first quarter of 2011.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.